#$%^&*AU2019204699A120190718.pdf#####Abstract The present invention relates to compositions, uses and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th Ienvironment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.1/1 IL12Ilevel in the blood of patient #11during the CFB protocol 300,0009- -200,00 o - -12 0,000 - -..... - -- - -... ； -00,000 CL O ,0 - -. -.. -- 0'3 6 9 12 0 210 240 270 ge3 Treatment CIyo+IV iv IV-B Start End IV-B IV-8 IV-B ofID/IVprotoco IV-B FIGURE 1
